Environmental monitoring programme in the cell therapy facility of a research centre: Preliminary investigation

Journal of Preventive Medicine and Hygiene

Volumn 51, Issue 4, 2010, Pages 133-138

  Ottria, G ^a   Dallera, M ^a   Aresu, O ^b   Manniello, M A ^b   Parodi, B ^b   Spagnolo, A M ^a   Cristina, Maria Luisa ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cell therapy; Environmental monitoring; Good Manufacturing Practice (GMP)

Indexed keywords

AIR POLLUTION; AIRBORNE PARTICLE; ARTICLE; BACTERIAL LOAD; CELL THERAPY; COLONY FORMING UNIT; CONTROLLED STUDY; ENVIRONMENTAL MONITORING; LABORATORY; MEDICAL EDUCATION; MICROBIAL CONTAMINATION; NONHUMAN; REFERENCE VALUE; BACTERIAL COUNT; FUNGUS; GOOD MANUFACTURING PRACTICE; QUALITY CONTROL; SURFACE PROPERTY;

AIR MICROBIOLOGY; BIOLOGICAL SPECIMEN BANKS; CELLS, CULTURED; ENVIRONMENT, CONTROLLED; ENVIRONMENTAL MONITORING; HUMANS; PARTICLE SIZE; QUALITY CONTROL; TISSUE THERAPY;

EID: 79953844517     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Burger SR. Current regulatory issues in cell and tissue therapy. Cytotherapy 2003;5:289-98. (Pubitemid 37264995)
2. European Commission Guide to Good Manufacturing Practices. Medicinal Products for human and veterinary use 1998 EudraLex vol. 4.
3. European Union Directive 2003/94/EC of 8 October 2003.
4. European Union Directive 2004/23/EC of the European Parliament and the Council of March 31 2004.
5. European Union Directive 2005/28/EC of 8 April 2005.
6. European Union Regulation 2004/726/EC of the European Parliament and of the Council of 31 March 2004.
7. European Union Regulation 2007/1394/EC of the European Parliament and of the Council of 13 November 2007.
8. Bosse R, Singhofer-Wowra M, Rosenthal F, et al. Good manufacturing practice production of human stem cells for somatic cell and gene therapy. Stem Cells 1997;15:275-80.
9. McCullough J. Quality assurance and good manufacturing practices for processing hematopoietic progenitor cells. J Hematother 1995;4:493-501. (Pubitemid 26020552)
10. Smith L, Lowdell MW. Quality issues in stem cell and immunotherapy laboratories. Transfus Med 2003;13:417-423. (Pubitemid 37549039)
11. Bosse R, Kulmburg P, Von Kalle C, et al. Production of stem-cell transplants according to good manufacturing practice. Ann Hematol 2000;79:469-76.
12. Cobo F, Stacey GN, Hunt C, et al. Microbiological control in stem cell banks: approaches to standardisation. Appl Microbiol Biotechnol 2005;68:456-66. (Pubitemid 41549989)
13. Griesel C, Heuft HG, Herrmann D, et al. Good manufacturing practice-compliant validation and preparation of BM cells for the therapy of acute myocardial infarction. Cytotherapy 2007;9:35-43. (Pubitemid 46992965)
14. Legislative Decree 211 Implementation of Directive 2001/20/EC, Rome.
15. European Commission Guide to Good Manufacturing Practice. Manufacture of sterile medicinal products 2003 revision to Annex 1. EC, Brussels.
16. European Commission Guide to Good Manufacturing Practice. Manufacture of sterile medicinal products 2008 revision to Annex I. EC, Brussels.
17. European Union Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001.
18. European Committee for Standardization Clean room technology. Design, construction and operation of clean rooms and clean air devices. European Prestandard 1996 ENV 1631
19. International Organization for Standardization ISO 14644-1. Cleanrooms and associated controlled environments 1999. Classification of air cleanliness.
20. International Organization for Standardization ISO 14644-4. Cleanrooms and Associated Controlled Environments 2001. Design, construction and start-up.
21. Hertroys R, Van Vught PA, Van De Donk HJ. Moving towards a microbiological environmental monitoring programme that can be used to release aseptically produced pharmaceuticals: a hypothesis. PDA J Pharm Sci Technol 1997;51:52-59. (Pubitemid 27443534)
22. Burger SR. Design and operation of a current good manufacturing practices cell-engineering laboratory. Cytotherapy 2000;2:111-122. (Pubitemid 30449428)
23. Cobo F, Concha A. Environmental microbial contamination in a stem cell bank. Lett Appl Microbiol. 2007;44:379-86. (Pubitemid 46496379)
24. Liguori G, Spagnoli G, Agozzino E, et al. Biological risk in the operatine room: microbiological monitoring of the environment and analysis of the associated variables. Annali di Igiene 2005;17:385-400.
25. Ljungqvist B, Reinmuller B. Airborne viable particles and total number of airborne particles: comparative studies of active air sampling. PDA J Pharm Sci Technol 2000;54:112-6. (Pubitemid 30321140)
26. Cobo F, Stacey GN, Cortes JL, et al. Environmental monitoring in stem cell banks. Applied Microbiology and Biotechnology 2006;70:651-62. (Pubitemid 43760500)
27. Pasquarella C, Pitzurra O, Savino A. The index of microbial air contamination. J Hosp Infect 2000;46:241-56.
28. Aycicek H, Oguz U, Karci K. Comparison of results of ATP bioluminescence and traditional hygiene swabbing methods for the determination of surface cleanliness at a hospital kitchen. Int J Hyg Environ Health 2006;209:203-6. (Pubitemid 43292309)
29. Ederer GM, Christian DL. Evaluation of bacteriological transport systems. Am J Med Technol 1975;41:299-306.
30. European Pharmacopoeia. Sterility 2004. Maisonneuve SA, Sainte Ruffine.
31. United States Pharmacopoeia. General Chapter 71 2004 Sterility tests. USP 27-NF 22. In: US Pharmacopoeial convention. Rockville, Maryland, 2004, pp. 2157-2162.
32. International Organization for Standardization ISO 14644-2. Cleanrooms and associated controlled environments. Specifications for testing and monitoring to prove continued compliance with ISO 14644-1, 2000.